841.30 -1.25 (-0.15%)

New 52W High today

2.4M NSE+BSE Volume

NSEOct 14, 2021 03:31 PM



841.30
-0.15%
default
841.30
-0.15%
Business Line
Motilal OswalSun Pharma (Buy)Target: 960CMP: 842.5After having toughed out for more than three years in the US, its flagship product Ilumya is conti
841.30
-0.15%
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Notice Of The Board Meeting ...
BSE India
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2021 ,inter alia, to consider and approve This is to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, November 02, 2021 to inter alia consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2021. Further, kindly note that pursuant to the Company''s Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons, commenced on October 01, 2021, and shall end on November 04, 2021 i.e. after 48 hours of the declaration of financial results of the Company on November 02, 2021. This is for your information and dissemination.
841.30
-0.15%
Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, ...
BSE India
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed certificate dated October 8, 2021 for the quarter ended September 30, 2021 received from M/s. Link Intime (India) Private Limited, Registrar & Share Transfer Agent of the Company. This is for your information and record.
default
841.30
-0.15%
Motilal Oswal
After having toughed out for more than three years in the US, its flagship product Ilumya is continuously ramping-up sales, with Cequa also showing good traction. This is slightly offset by generic competition in Absorica and difficulty in shifting prescriptions to Absorica LD. Ilumya has been able to carve out a niche for itself in the fiercely competitive Psoriasis segment. Ilumya, being a medical benefit product, does not directly compete with most drugs which fall into the Pharmacy benefits segment. Its new mechanism of action, fewer dosage, and low sideeffects also bode well for better uptake....
Sun Pharmaceutical Industries Ltd. has gained 67.52% in the last 1 Year
841.30
-0.15%
Firm US sales keep Sun Pharma's outlook upbeat
Firm US sales keep Sun Pharma's outlook upbeat
livemint
The firm has been banking on its unfolded speciality portfolio in the US to support growth and thus offset some of the pricing pressure in the US generics base business
Sun Pharmaceutical Industries Ltd. is trading above all available SMAs
841.30
-0.15%
Sun Pharmaceutical Industries Q2 PAT seen up 15.6% YoY to Rs 2,094.8 cr: Prabhudas Lilladher
Sun Pharmaceutical Industries Q2 PAT seen up 15.6% YoY to Rs 2,094.8 cr: Prabhudas Lilladher
Moneycontrol
Net Sales are expected to increase by 13.3 percent Y-o-Y (down 0.9 percent Q-o-Q) to Rs 9,584.3 crore, according to Prabhudas Lilladher.
Sun Pharmaceutical Industries Ltd. has gained 67.52% in the last 1 Year
841.30
-0.15%
Business Line
Sun Pharmaceutical Ind (826.6)Breaks out afreshThe stock of Sun Pharmaceutical Industries, which has been on a steady rise since November last year a
default
Sun Pharmaceutical Industries Ltd. has gained 67.52% in the last 1 Year
841.30
-0.15%
default
841.30
-0.15%
Sun Pharma gains 4% in 2 days after launching cough syrup Chericof 12
Sun Pharma gains 4% in 2 days after launching cough syrup Chericof 12
Business Standard
Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug
Sun Pharmaceutical Industries Ltd. has gained 34.10% in the last 6 Months
Total Votes: 1319
BUY
SELL
HOLD
74.37%
16.83%
8.79%